ÒÖëÄø¶ÔÐÄÔàÌåÍâÑ­»·ÊõºóTNF-¦ÁˮƽµÄÓ°Ïì

À´Ô´£ºÑ°Ò½ÎÊÒ©Íø¡¡Ñ°Ò½ÎÊÒ©Íø

ÍÆ¼öÔĶÁ
     ×÷ÕߣºÁõÁ¢Ã÷ ºú½¨¹ú ÐìÃô

    µ¥Î»£ºÁõÁ¢Ã÷(µÚ¶þ¸½ÊôÒ½ÔºÐÄÐØÍâ¿Æ ³¤É³ 410011)£»ºú½¨¹ú(µÚ¶þ¸½ÊôÒ½ÔºÐÄÐØÍâ¿Æ ³¤É³ 410011)£»ÐìÃô(µÚ¶þ¸½ÊôÒ½ÔºÐÄÐØÍâ¿Æ ³¤É³ 410011)

    ¹Ø¼ü´Ê£ºÒÖëÄø£»ÌåÍâÑ­»·£»Ï¸°ûÒò×Ó*£»È«ÉíÑ×Ö¢·´Ó¦*

    ºþÄÏÒ½¿Æ´óѧѧ±¨000225[ÕªÒª] ²ÉÓÃË«¿¹Ìå¼ÐÐÄøÁªÃâÒßÎü¸½·¨²â¶¨²»Í¬¼ÁÁ¿ÒÖëÄ Ã¸¶ÔÐÄÔàÌåÍâÑ­»·(CPB)ÊõÖÐÖ×Áö»µËÀÒò×Ó-¦Á(TNF-¦Á)µÄº¬Á¿¡£½á¹ûÏÔʾ£ºCBPÊõºó24h Ѫ½¬TNF-¦Áº¬Á¿£¬ÔÚÈ«Á¿ÒÖëÄø×é½Ï¶ÔÕÕ×éÓÐÃ÷ÏÔ½µµÍ(P<0.05)£»ÔÚµ¥´Î¼ÁÁ¿ÒÖëÄø ×é½Ï¶ÔÕÕ×éÎÞ²îÒì(P<0.05)¡£±íÃ÷È«Á¿ÒÖëÄø¾ßÓп¹Ñ×Ч¹û¡£

    [ÖÐͼ·ÖÀàºÅ] R654.1£¬R654.2 [ÎÄÏ×±êʶÂë] A [ÎÄÕ±àºÅ] 1000-5625(2000)02-0166-03

    Effects of Aprotinin on TNF-¦Á levels after cardiopulmonary by pass

    LIU Li-ming, HU Jian-guo, XU Min

    Department of Cardiothoracic Surgery, The Second Affiliated Hospital, Hun an Medical University(Changsha 410011)

    [Abstract] Objective: This study evaluates the anti-inflammat o ry activity of full-dose and pump-prime-only(low-dose) aprotinin by means of comparing tumor necrosis factor ¦Á(TNF-¦Á) levels of both groups after CPB. Me thods: Twenty-nine adults with rheumatic heart disease were randomized into thr ee groups: (1)full-dose aprotinin-treated group(Group A, n=10); (2)pump-p rime-only aprotinin-treated group(Group B, n=10), and (3) control group(Gr oup C, n=9). Plasma concentrations of TNF-¦Á were measured by enzyme-linke d immunosorbent assay technique at baseline(before operation), and at 2,24 hours after CPB termination. Results: A significant(P<0.05) increase of TNF-¦Á o ccurred in all three groups at 2 and 24 hours after CPB termination when compare d with the same group at baseline. In Group A, TNF-¦Á level was significantly l ower than that in group C(P<0.05) at 24 hours after CPB, but not in group B (P>0.05). Conclusions: Both CPB and operative stimulus induce the increase o f cytokine TNF-¦Á after CPB. Full-dose aprotinin has the anti-inflammatory ef fect by means of reducing TNF-¦Á level after CPB. Low-dose aprotinin dose not reduce TNF-¦Á level. So it no significant anti-inflammatory effect.

    [Key words] cardiopulmonary bypass; cytokine; systemic infl ammatory response; aprotinin

    ÌåÍâÑ­»·(CPB)ÐÄÔàÊÖÊõËùÖµÄÈ«ÉíÑ×Ö¢·´Ó¦£¬¿ÉÒÔÒýÆð ÊõºóÑÏÖØµÄ²¢·¢Ö¢¼°Ôö¼ÓÊÖÊõËÀÍöÂÊ[1]¡£×÷ÎªÖØÒªµÄÑ×Ö¢½éÖÊ£¬Ï¸°ûÒò×ÓÊÇÈ«Éí Ñ×Ö¢·´Ó¦²úÉúÓë·¢Õ¹¹ý³ÌÖеÄÖÐÐÄ»·½Ú¡£½üÄ꣬¹úÍâѧÕß±¨µÀÓ¦ÓÃÈ«Á¿ÒÖëÄø¿ÉʹCPBÊõºó ¼õÉÙ´ÙÑ×֢ϸ°ûÒò×ÓÊÍ·Å£¬Ôö¼Ó¿¹Ñ×֢ϸ°ûÒò×Ó°×ϸ°û½éËØ10(IL010)µÈµÄÊÍ·Å£¬ÒÖÖÆµ°°× Ë®½âø²úÎï¼°²¹Ìå¡¢ÖÐÐÔÁ£Ï¸°ûµÄ¼¤»î[2£¬3]£¬ÌáʾȫÁ¿ÒÖëÄø¿ÉÒÖÖÆCPBÊõºó È«ÉíÑ×Ö¢·´Ó¦¡£±¾Ñо¿Í¨¹ý±È½ÏÓ¦ÓÃÈ«Á¿ÒÖëÄø¼°Ô¤³äÒºµ¥´Î¼ÁÁ¿ÒÖëÄø¶ÔCPBÊõºóÖ×Áö»µ ËÀÒò×Ó¦Á(TNF-¦Á)Ѫ½¬Å¨¶ÈµÄÓ°Ï죬½øÒ»²½Ì½ÌÖ²»Í¬¼ÁÁ¿ÒÖëÄøÔÚCPBÐÄÔàÊÖÊõÖеĿ¹Ñ××÷ Óá£

    1 ¶ÔÏóÓë·½·¨

    1.1 ¶ÔÏó ³ÉÈË·çʪÐÔÐÄÔಡ29Àý£¬ÄÐ11Àý£¬Å®18Àý£¬Æ½¾ùÄêÁä36.7¡À6 .8(18¡«55)Ëê¡£½«29Àý²¡ÈË·Ö³É3×飺A×é(È«Á¿ÒÖëÄø×é)£¬¼´ÔÚÂé×íÓÕµ¼ºó»ºÂý¾²Âö×¢Éä ÒÖëÄø200ÍòKIU(Ï൱ÓÚ280mg)£¬ÔÙÏòÐķλúÔ¤³äÒºÖÐ×·¼Ó200ÍòKIU£¬ÓÚÊÖÊõÈ«¹ý³ÌÒÔÿ Сʱ50ÍòKIUµÄËٶȳÖÐø¾²µÎÖ±ÖÁÊÖÊõ½áÊø£»B×é(Ô¤³äÒºµ¥´Î¼ÁÁ¿ÒÖëÄø×é)£¬¼´½«ÒÖëÄøµÄ 200ÍòKIUÒ»´ÎÐÔ×¢ÈëÔ¤³äÒºÖУ¬²»ÔÙ×·¼Ó»òά³Ö£»C×é(¶ÔÕÕ×é)£¬ÊõÖÐδÓÃÒÖëÄø¡£·Ö×鲡 Àý×ÊÁϼû±í1¡£

    ±í1 ²¡Àý·Ö×é¼°Ò»°ã×ÊÁϱȽÏ( ¡Às) ×é±ð

    n

    ÐÔ±ð

    (ÄÐ/Å®)

    ÄêÁä

    (Ëê)

    ÌåÖØ

    (kg)

    CPBʱ¼ä

    (min)

    Ö÷¶¯Âö×è¶Ï

    Ê±¼ä(min)

    A

    10

    4/6

    38.3¡À5.5

    55.2¡À3.0

    85.6¡À5.3

    57.5 ¡À4.1

    B

    10

    3/7

    37.4¡À4.6

    54.5¡À3.1

    81.8¡À5.0

    55.8¡À4 .0

    C

    9

    4/5

    34.6¡À4.9

    56.2¡À2.8

    82.3¡À5.2

    56. 3¡À4.3

    ÒÔÉϲ¡Àý¾ùÅųýºÏ²¢ÐÄÄÚĤÑס¢ÌÇÄò²¡¡¢ÑÏÖØÐÄË¥ÒÔ¼°¸Î¡¢Éö¹¦Äܲ»È«µÈ¼²²¡£¬ÇÒÊõǰ¡¢ÊõÖС¢Êõºó24hÄÚ¾ùδʹÓÃÌÇÆ¤Öʼ¤ËØ¡¢ÉöÉÏÏÙËØ¡¢ÃâÒßÒÖÖÆ¼Á¡¢°¢Ë¹Æ¥ÁÖµÈÒ©ÎïÖÎÁÆ¡£

    1.2 ·½·¨

    1.2.1 Âé×í¼°ÌåÍâÑ­»·µÄ½¨Á¢ 29Àý»¼Õß¾ùÔÚCPBÏÂÐаêĤֱÊÓÊÖÊõ£¬³£¹æÓþ²Âö ÎüÈ븴ºÏÂé×í(Ò©ÎïΪPropofol,Fentanyl,Domirium,Norcuron)£¬²¢×÷Æø¹Ü²å¹Ü¼°½¨Á¢¼à²â ϵͳ¡£CPB²ÉÓÃSarns 9000»òSTKÐķλú£¬¹öѹʽѪ±ÃºÍÎ÷¾©90Ð͹ÄÅÝʽÈ˹¤·Î£¬Ç³µÍÎÂÖÁÖÐ µÍÎÂ(28¡æ¡«32¡æ)¡£CPB¹àÁ÷ËÙ¶ÈΪ2.0¡«2.4L.min-1.m-2£¬¶¯Âöѹά³Ö ÔÚ50¡«80mmHg(ƽ¾ùѹ)£¬Ð£»¤²ÉÓÃ˳¹àÀä¸ß¼Ø¾§ÌåÐÄÔàÍ£ÌøÒº£»ÓøÎËØ(3mg.kg -1)¿¹Äý£¬ACT¼à²â£¬±£³ÖACT²»ÉÙÓÚ480s£¬Í£»úºó³£¹æÓÃ100mgÓ㾫µ°°×Öк͸ÎËØ£¬ ²âACT£¬±ØÒªÊ±¿É×·¼ÓÉÙÁ¿Ó㾫µ°°×¡£ÐÄÔàÍ£ÌøÒºÖм°Í£»úºó¾ùδʹÓÃÌÇÆ¤Öʼ¤ËØ¡£

    1.2.2 ±ê±¾µÄ»ñÈ¡Óë±£´æ ·Ö±ðÓÚÊÖÊõ¿ªÊ¼Ç°¡¢CPBÍ£»úºó2h¼°CPBÍ£»ú ºó24h 3¸öʱ¼äµãλ³éÈ¡1.8ml¾²ÂöѪÖÃÈ뺬0.2mlèÛéÚËáÄÆÎÞ¾úÊÔ¹ÜÄÚ(9¡Ã1)¡£Ñª ±ê±¾Á¢¼´ÒÔ3000rpmÀëÐÄ10min£¬»ñȡѪ½¬ºóÁ¢¼´·Ö×°ÓÚ-20¡æ±ùÏäÖÐÀä¶³±£´æ¡£

    1.2.3 TNF-¦ÁµÄ²â¶¨ ÓÃElx800ø±êÒÇ(Bio-Tek Instrument, ITC)£¬ ÈËTNF-¦Á ELISAÊÔ¼ÁºÐ(ÉîÛÚ¾§ÃÀÉúÎ﹤³ÌÓÐÏÞ¹«Ë¾)£¬ÒÖëÄø(Àö±¦ÉúÎï»¯Ñ§ÖÆÒ©ÓÐÏÞ¹«Ë¾ ²ú)¡£°´ÊÔ¼ÁºÐ˵Ã÷Êé²Ù×÷£¬²ÉÓÃË«¿¹Ìå¼ÐÐÄELISA·¨(øÁªÃâÒßÎü¸½·¨)²âµÃ±ê׼Ʒ¼°¸÷Ñù±¾ ODÖµ£¬ÒÔ±ê׼ƷŨ¶È×÷ºá×ø±ê£¬ODÖµ×÷×Ý×ø±ê£¬»æÖƱê×¼ÇúÏߣ¬¸ù¾ÝODÖµ¿ÉÔÚ±ê×¼ÇúÏßÉÏ·Ö ±ð²é³ö¸÷ÑùƷŨ¶È¡£

    1.3 ͳ¼ÆÑ§´¦Àí Êý¾Ý½á¹ûÓþùÊý¡À±ê×¼²î(¡Às)±íʾ£¬Èý×é ¼äÁ½Á½±È½ÏÓÃq¼ìÑé¡£

    2 ½á ¹û

    29Àý»¼ÕßÊõÖоùƽÎÈ£¬Ë³ÀûÍÑ»ú£¬ÓÚÊõºóµÚ1¡«3dת³öICU£¬ÎÞÔٴοªÐØÖ¹Ñª»òÑÏÖØ²¢·¢Ö¢ Õߣ¬ÎÞËÀÍö²¡Àý¡£Èý×鲡ÀýTNF-¦ÁѪ½¬Å¨¶È¼ì²â½á¹û¼û±í2¡£

    ±í2 Èý×鲡ÀýTNF-¦ÁˮƽµÄ±ä»¯(¡Às) ×é±ð

    ÀýÊý

    Êõǰ

    CPBºó(h)

    2

    24

    A

    10

    3.51¡À0.63

    11.39¡À1.87¢Ù

    4 .68¡À0.80¢Ù¢Ú

    B

    10

    3.43¡À0.68

    11.03¡À1.92¢Ù

    9.21¡À1.05¢Ù

    C

    9

    3.58¡À0.57

    10.81¡À1.75¢Ù

    8.83¡À1.13¢Ù

    ¢ÙÓëͬ×éÊõǰ±È½ÏP<0.05£»¢ÚÓëB»òC×éͬʱ¼ä±È½ÏP<0.05

    Èý×鲡ÀýTNF-¦ÁѪ½¬Å¨¶ÈÊõǰ»ù´¡Öµ¾ù½ÏµÍ£¬×é¼ä±È½Ï²îÒìÎÞÏÔÖøÐÔ(P>0.05) £»CPBºó2h¼°CPBºó24h TNF-¦ÁˮƽÓëͬ×éÊõǰ±È½ÏÓÐÃ÷ÏÔÉý¸ß(P<0.05)£¬Æä×î¸ß Öµ¾ù³öÏÖÔÚCPBÍ£»úºó2h¡£ÔÚCPBºó24h£¬A×éTNF-¦ÁˮƽÓëC×é»òB×é±È½Ï£¬¾ùÓÐÃ÷ÏÔ½µ µÍ(P<0.05)£»¶øB×éÓëC×é±È½Ï²îÒìÎÞÏÔÖøÐÔ(P>0.05)¡£Èý×éTNF-¦ÁˮƽÔÚCPBºó2 h±È½Ï²îÒìÎÞÏÔÖøÐÔ(P>0.05)¡£

    3 ÌÖ ÂÛ

    ÌåÍâÑ­»·ÐÄÔàÊÖÊõËùÖµÄÈ«ÉíÑ×Ö¢·´Ó¦ÊǽüÄ걸ÊÜÈËÃǹØ×¢µÄÎÊÌâ¡£´óÁ¿ÊµÑé¼°ÁÙ´²Ñо¿±í Ã÷£¬CPBËùÖµÄÈ«ÉíÑ×Ö¢·´Ó¦Óëϸ°ûÒò×ÓˮƽµÄ±ä»¯¼°×÷ÓÃÓÐ×ÅÃÜÇеÄÁªÏµ[4]£¬ È«ÉíÑ×Ö¢·´Ó¦¿ÉÒýÆðCPBÊõºóÐÄÔà¡¢·ÎȱѪÔÙ¹à×¢ËðÉ˼°¶àÆ÷¹Ù¹¦ÄÜË𺦣¬¶ÔCPBÊõºó²¢·¢Ö¢ µÄ·¢Éú¼°Ô¤ºóÆð׏ؼü×÷Óá£ÔÚCPB¹ý³ÌÖм°ÊõºóѪ½¬´ÙÑ×֢ϸ°ûÒò×ÓÓ뿹Ñ×֢ϸ°ûÒò×ÓŨ ¶È¾ùÓв»Í¬³Ì¶ÈµÄÉý¸ß£¬±¾Ñо¿½á¹ûÏÔʾ£¬Èý×鲡ÀýCPBºó2h¼°CPBºó24h TNF-¦Áˮƽ ½ÏÊõǰ»ù´¡Ë®Æ½¾ùÓÐÃ÷ÏÔÉý¸ß(P<0.05)£»TNF-¦Áˮƽ×î¸ßÖµ¾ùÔÚCPBºó2h³öÏÖ£¬ÓÚCP Bºó24h½µµÍÖÁ½ÏµÍˮƽ(µ«½ÏÊõǰÈÔÓÐÉý¸ß)£¬ÓëMcBrideµÈ[5]£¬WanµÈ[5 ]±¨µÀÏà·û¡£

    CPBËùÖµÄ×éÖ¯Æ÷¹ÙȱѪÔÙ¹à×¢ËðÉËÊÇCPBºóϸ°ûÒò×Ó²úÉúÓëÊͷŵÄÊ×ÒªÒòËØ¡£Ï¸°ûÒò×ÓÖ÷Òª ×÷ÓÃΪϸ°û¼äÐÅʹ£¬½éµ¼¡¢¼¤»î¸÷ÖÖÑ×ÐÔϸ°û(ÈçÄÚÆ¤Ï¸°û¡¢ÖÐÐÔÁ£Ï¸°û¡¢ÁܰÍϸ°ûµÈ)£¬Ê¹ Ö®ÊÍ·Å´óÁ¿Ñª¹Ü»îÐÔ¼°Ï¸°û¶¾ÐÔÎïÖÊ£¬Ôö¼ÓÕ³¸½·Ö×Ó±í´ï£¬´Ù½ø»î»¯ÖÐÐÔÁ£Ï¸°ûÓëÄÚÆ¤Ï¸°û µÄÕ³¸½×÷Ó㬴Ӷø´Ù½øÑ×Ö¢·´Ó¦µÄ½ø³Ì£¬µ¼ÖÂCPBÐÄÔàÊÖÊõºó¶àÖÖ²¢·¢Ö¢¡£ÔÚÖî¶à´ÙÑ×֢ϸ °ûÒò×ÓÖУ¬TNF-¦ÁÊÇÑ×Ö¢·´Ó¦¹ý³ÌÖÐÊÍ·Å×îÔç¡¢×îÖØÒªµÄÄÚÔ´ÐÔÑ×Ö¢½éÖÊÖ®Ò»£¬µ«ÆäCPBºó Ũ¶È²â¶¨½á¹û¸÷±¨µÀ²»Ò»£¬TNF-¦ÁÓдٽøIL-1£¬IL-6£¬IL-8£¬IL-10¼°TNFÊÜÌåµÈÊÍ·Å µÄ×÷Óã¬ÓÐѧÕß½«ÆäÃèÊöΪȫÉíÑ×Ö¢·´Ó¦Öеġ°°â»ú¡±£¬¶øÌåÒºÖÐÖÚ¶àµÄϸ°ûÒò×ÓÍøÂç¼äµÄ Ï໥×÷Ó㬿ÉÄÜÊÇÔàÆ÷ÊÜËðµÄÖØÒªÒòËØ¡£±¾Ñо¿½á¹û±íÃ÷£¬ÔÚÈ«Á¿ÒÖëÄø×éTNF-¦ÁѪ½¬Å¨ ¶ÈÓÚCPBºó24h½Ï¶ÔÕÕ×é(°üÀ¨µ¥´Î¼ÁÁ¿ÒÖëÄø×é)ÓÐÃ÷ÏÔ½µµÍ(P<0.05)£»¶øÈý×é¼äCPB ʱ¼ä¡¢Ö÷¶¯Âö×è¶Ïʱ¼ä¾ùÎÞ²îÒì(±í1)¡£HillµÈ[3£¬6]ÈÏΪ£¬È«Á¿ÒÖëÄø¿ÉÒÔÔö ¼ÓCPBÊõºóIL-10µÄÊÍ·Å£¬ËüÓëÌÇÆ¤Öʼ¤ËØ¡¢ÉöÉÏÏÙËØÓÐÀàËÆµÄ¿¹Ñ×Ч¹û¡£Ò²ÓÐѧÕßÈÏΪ£¬ ÒÖëÄø¿É½µµÍCPBÊõºóѪ½¬ÖÐTNF-¦Á£¬IL-6£¬IL-8Ũ¶È¼°ÕûºÏËØCD11bµÄ±í´ï[6£¬ 7]¡£

    ÒÖëÄøÔÚCPBÐÄÔàÊÖÊõÖеÄÓÃÒ©¼ÁÁ¿Ò»Ö±ÊÇÈËÃǹØ×¢µÄÎÊÌ⣬³ý±¾Ñо¿ÖÐʹÓõÄÁ½ÖÖÓ÷¨Íâ £¬»¹ÓÐÒ»Öֽϳ£ÓõİëÁ¿ÒÖëÄø·¨£¬ÆäÓ÷¨ÓëÈ«Á¿ÒÖëÄø·¨Ïàͬ£¬µ«¼ÁÁ¿¾ù¼õ°ë¡£ÒÖëÄøÔÚ CPBÐÄÔàÊÖÊõÖзÀÖηÇÍâ¿ÆÐÔÉøÑªµÄЧ¹ûÒѵõ½¹úÄÚÍâѧÕߵįձéÈÏͬ¡£´óÁ¿±¨µÀÏÔʾ£¬ÉÏ ÊöÈýÖÖÒÖëÄøÓ÷¨¾ù¿É¸ÄÉÆCPBÊõºóÄýѪ£¬ÄÜÓÐЧ½µµÍÊõºóʧѪ£¬µ«ÒàÓб¨µÀÈÏΪӦÓõ¥´Î ¼ÁÁ¿ÒÖëÄøÎÞЧ[8]¡£È«Á¿ÒÖëÄø¿ÉÒÔÒÖÖÆCPBËùÖÂÑ×Ö¢·´Ó¦[2£¬3]£» °ëÁ¿ÒÖëÄøÒàÓп¹Ñ×Ч¹û[6]£»µ«ÉÐδ·¢ÏÖÓ¦Óõ¥´Î¼ÁÁ¿ÒÖëÄøÔÚCPBÊõÖÐʹÓÃÓÐ ¿¹Ñ×Ч¹ûµÄ±¨µÀ¡£±¾Ñо¿½á¹ûҲ֤ʵȫÁ¿ÒÖëÄø×éÓÚCPBÊõºó24h£¬TNF-¦Áˮƽ½Ï¶ÔÕÕ×é Ã÷ÏÔ½µµÍ(P<0.05)£»¶øµ¥´Î¼ÁÁ¿ÒÖëÄø×é(С¼ÁÁ¿)Óë¶ÔÕÕ×é±È½Ï²îÒìÎÞÏÔÖøÐÔ( P>0.05)¡£ÌáʾӦÓÃÈ«Á¿ÒÖëÄø¿ÉÒÔÒÖÖÆCPBËùÖµÄÈ«ÉíÑ×Ö¢·´Ó¦£¬ÓÐÀûÓÚCPBÐÄÔàÊÖÊõ ºóµÄ»Ö¸´²¢·ÀÖ¹²¢·¢Ö¢µÄ·¢Éú¡£

    ²Î¿¼ÎÄÏ×£º

    [1] Steinberg JB, Kapelanski DP, Olson JD. Cytokine and comp lement levels in patients undergoing cardiopulmonary bypass[J]. J Thorac Cardi ovasc Surg, 1993,106:1008-1016.

    [2] Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibitis the cont act, neutrophil, and platelet activation systems during simulated extracorporeal perfusion[J]. J Thorac Cardiovasc Surg, 1993,106:1-10.

    [3] Huill GE, Robert P, Diego, et al. Aprotinin enhances the endogenous r elease of interleukin-10 after cardiac operation[J]. Ann Thorac Surg, 1998,65 :66-69.

    [4] Wan S, Marchant A, DeSment JM, et al. Human cytokine responses to car diac tansplantation and coronary artery bypass grafting[J]. J Thorac Cardiovas c Surg, 1996,11:469-477.

    [5] McBride WT, Armstrong MA, Crokard AD, et al. Cytokine balance and imm unosuppressive changes at cardiac surgery: contrasting response between patients and isolated CPB circuits[J]. Br J Anaesth, 1995,75:724-733.

    [6] Hill GE, Alonso A, Spurzen JR, et al. Aprotinin and methylprednisolon e equally blunt cardiopulmonary bypass-induced inflammation in human[J]. J Th orac Cardiovasc Surg, 1995,110:1658-1662.

    [7] Hill GE, Pohorecki R, Alonso A, et al. Aprotinin reduces interleukin -8 production and lung neutrophil accumulation after cardiopulmonary bypass[J ]. Anesth Analg, 1996,83:696-700.

    [8] Jeffey B, Rich MD. The efficacy and safety of aprotinin use in cardiac su rgery[J]. Am Thorac Surg, 1998,66:S6-11. (ÎÄÕ³ö´¦£ººþÄÏÒ½¿Æ´óѧѧ±¨ 2000ÄêµÚ2ÆÚµÚ25¾í)
Ïà¹ØÎÊ´ð£º
  • ×ö°®¶ÔÐÄÔàÓкÎÓ°Ïì
  • £Ô²¨¸Ä±ä¶ÔÐÄÔàµÄÓ°Ï죿
  • ijЩÖÐÒ©¶ÔÐÄÔàÊÇ·ñÓÐÓ°Ï죿лл£¡
  • ¿§·È¶ÔÐÄÔಡӰÏì´óÂð
  • ÃÀÂåÎô¿µ¶ÔÐÄÔಡµÄÓ°Ïì
  • θ²¡¶ÔÐÄÔàÓÐÓ°ÏìÂð£¿
  • ¸Îµ¨¼²²¡¶ÔÐÄÔàÔ粨ÓÐʲôӰÏ죿
  • ¶ÔÐÄÔà´îÇÅÊÖÊõºóµÄ»¼ÕßÈçºÎ»¤Àí
  • ¹ØÓÚÖÐÒ©¶ÔÐÄÔàµÄÓ°ÏìµÄ¼ÌÐøÎÊÌâ
  • ÊÖÒù¶ÔÐÄÔàºÍ˯ÃßÓÐûÓÐÓ°Ïì

  • Ïà¹Ø×ÊѶ£º
  • ÒÖëÄøÊг¡·ÖÎö±¨¸æ
  • Ó°ÏìѪ֬ˮƽµÄÒ©ÎïÓÐÄÄЩ£¿
  • ÄÜÓ°ÏìѪ֬ˮƽµÄÒ©Îï
  • Ó°ÏìѪ֬ˮƽµÄÒ©ÎïÓÐÄÄЩ£¿
  • ÌåÍâÑ­»·ÖеÄÐÄÔàµÄ΢ѭ»·
  • TNF-¦ÁÓëÖÐÄêÄÐÐÔÔçÆÚ¶¯ÂöÖàÑùÓ²»¯Ïà¹Ø
  • ¸ßѪѹ¶ÔÐÄÔàÓкÎÓ°Ïì
  • ̽ÌÖÒÖÓô¶ÔÐÄÔàµÄÓ°Ïì
  • ¸ßѪѹ¶ÔÐÄÔàÓкÎÓ°Ïì
  • ʲôÊÇÌåÍâÑ­»·ÊÖÊõ
  • ½¡¿µÍ¼Æ×
    ½¡¿µÉ̳Çhttp://shop.xywy.com ½¡¿µ¹ºÎïºÃÈ¥´¦
    ÓÑÇéÁ´½Ó